A quarter of people seeking care for symptoms of chronic respiratory diseases in Kenya may incur "catastrophic" health costs, ...

Digital inhalers that allow remote patient monitoring may predict impending exacerbations, or episodes when symptoms of COPD ...

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Chronic obstructive pulmonary disease (COPD) affects 25 million people in the U.S. and is the fifth leading cause of death ...

COPD has a large economic impact on the healthcare system and a destructive impact on the lives of patients and their ...

Research on the Digihaler highlights its potential to track COPD inhaler use, offering real-world data to improve treatment ...

Researchers discover an unusual accumulation of particles in people with the disease; the causes are still unclear.

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

Fatigue is one of the most common symptoms of COPD, so it's important to understand what causes it, columnist Caroline Gainer says.

Australians living with chronic obstructive pulmonary disease (COPD) are being exposed to greater health risks as the use of a critical diagnostic ...

Chronic breathlessness, coughing or excess mucus may seem minor, but they could signal chronic obstructive pulmonary disease.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.